Research Institutions & Projects

Dr. Stephen A. Curley, M.D., F.A.C.S.

In addition to his work with the Kanzius non-invasive radio-wave cancer treatment, Dr. Curley also serves as Professor of Surgical Oncology, Charles B. Barker Chair in Surgery, and Chief of Gastrointestinal Tumor Surgery at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. The M.D. Anderson Cancer Center is the largest cancer center in the world and is ranked as the #1 cancer center in the United States by US News and World Report Magazine; their mission is to eradicate human cancer as a source of disease and to find better methods to prevent cancer, and treat those stricken with this horrible disease.

Scope of Work:

Dr. Stephen Curley is the recipient of over $1.9 million in grants from the Kanzius Cancer Research Foundation. The purpose of these grants is to advance the study of the Kanzius non-invasive radio wave cancer treatment.

More specifically, this project is studying the use of the machine invented by the late John Kanzius to kill human cancer cells treated with targeted metallic nanoparticles. Dr. Curley is using antibodies, or peptides, that target human liver cancer, pancreatic cancer, colon cancer, prostate cancer, breast cancer, melanomic cancer, lung cancer, and leukemic cancer, and will treat all of these cancers both in vitro (Petri dishes) and in vivo (animals) with these malignant tumors. More than 400,000 people are diagnosed annually with these cancers; all stand to benefit from this research.

These grants have allowed Dr. Curley to expand the amount staff in his lab already working with the Kanzius machine to 14 people. This expansion will expedite the completion of the basic scientific requirements necessary to approach the United States Food and Drug Administration for permission to begin human clinical trials using the targeted metallic nanoparticles and the John Kanzius’ machine. Dr. Curley and his staff have already published numerous major manuscripts on this research and have several additional papers in preparation for submission.

The goals of this research are several:

Identify and test molecules that target human liver cancer, pancreatic cancer, colon cancer, prostate cancer, breast cancer, melanomic cancer, lung cancer, and leukemic cancer;
Demonstrate that increased uptake of gold and other metallic nanoparticles using agents targeting these types of cancer leads to killing of the cancer cells following treatment in the Kanzius machine;
Demonstrate that these targeted gold nanoparticles can be used to kill the same kind of cancers growing in animals; and
Build from these studies to treat all types of human cancer.

Simply stated, the completion of these goals will allow Dr. Curley to accrue the body of data necessary to approach the FDA to allow human clinical trials.

Donate Now to advance this research.